Holen Sie sich die Stockscreener-App
222.35
0.20%
0.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$222.00
Offen:
$221.52
24-Stunden-Volumen:
565.04K
Relative Volume:
0.41
Marktkapitalisierung:
$32.07B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
21.43
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
-0.52%
1M Leistung:
-7.45%
6M Leistung:
+0.89%
1J Leistung:
-17.70%
1-Tages-Spanne:
$218.26
$222.62
1-Wochen-Bereich:
$218.26
$227.90
52-Wochen-Spanne:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
222.35 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
414.93 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.95 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.31 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.03 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
Will ResMed (ASX:RMD) Keep Taking Share in Sleep Apnoea? - Kalkine Media
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed CEO Farrell: Every Hour of CPAP Use Cuts Healthcare Costs 7% - finance.biggo.com
What Is ResMed Signalling With Its Share Repurchase (ASX:RMD)? - Kalkine Media
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc. - MarketBeat
ResMed stock slips 0.73 percent ahead of the open - AD HOC NEWS
ResMed stock targets 12 to 14 percent EPS growth - AD HOC NEWS
ResMed stock heads into the open after a 0.2 percent gain - AD HOC NEWS
How Is ResMed Reshaping What It Owns (ASX:RMD)? - Kalkine Media
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand - MarketBeat
ResMed stock holds gains as analysts highlight sleep apnea growth - AD HOC NEWS
Weekly Recap: FY26 revenue & EPS growth and RBC upgrade, $1.5B buyback - TradingView
ResMed Inc. (RMD) Stock Analysis: A Healthcare Titan With A 10% Potential Upside - DirectorsTalk Interviews
ResMed Stock And Senior Healthcare Shares Linked To Medicare Spending Trends - simplywall.st
ResMed Inc. stock edges lower as analysts lift targets after recent results - AD HOC NEWS
ResMed stock gains on RBC upgrade and new institutional buying - AD HOC NEWS
ResMed Inc. stock gains on analyst upgrade and new investor interest - AD HOC NEWS
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures - Yahoo Finance
Nykredit A S Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Shares Jump Following RBC Capital Upgrade to Outperform - TIKR.com
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. - Barron's
ResMed stock jumps 3% on RBC Capital upgrade to Outperform - Investing.com
This Analyst Just Upgraded ResMed Stock. Here's Why. - Barchart.com
Why ResMed (RMD) Stock Is Up Today - Moomoo
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis - TradingKey
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says - marketscreener.com
ResMed Price Target Raised to $262.00/Share From $244.00 by RBC Capital - Moomoo
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
ResMed upgraded at RBC Capital Markets on Q4 positives - Seeking Alpha
RBC Capital Upgrades ResMed(RMD.US) to Buy Rating, Raises Target Price to $262 - Moomoo
Resmed Inc. : RBC Raises to Outperform From S - Moomoo
ResMed Stock: Is RMD Underperforming the Healthcare Sector? - finance.yahoo.com
ResMed Inc. (RMD) Stock Analysis: Exploring 12.90% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed Stock Slides 9.2% Over 9 Straight Down Days - Trefis
National Pension Service Has $54.85 Million Stock Position in ResMed Inc. $RMD - MarketBeat
WINTON GROUP Ltd Makes New Investment in ResMed Inc. $RMD - MarketBeat
Why Is ResMed (NYSE:RMD) Suddenly Drawing Attention? - Kalkine Media
ResMed Stock Is Up 13% in Three Months, The Buyback Is Doing the Heavy Lifting. Here’s What It Could Be Worth Before 2027. - TIKR.com
ResMed Inc. stock extends eight-day slide as market value drops - ad-hoc-news.de
ResMed Stock Slides 8.6% Over 8 Straight Down Days - Trefis
ResMed stock heads into the open after a 0.2% dip - ad-hoc-news.de
Is ResMed (ASX:RMD) the Steadier Name in Healthcare? - Kalkine Media
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):